Targets › HTR2A
68 programs from 56 companies in 432 trials: 184 Phase 2, 105 Phase 1, 81 Phase 4, 62 Phase 3; Psychiatry, Neurology, Other; next expected readout Nov 2026.
G protein-coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). (UniProt, P28223)
Open in Phaseline: the race on HTR2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johns Hopkins University | THC High Dose Serotonin 2a (5-HT2a) receptor inverse agonist | CNR1, HTR2A | Phase 4 | Opioid Use; Cystic Fibrosis; Tobacco Dependence; Multiple Sclerosis … | Nov 2026 |
| Vanderbilt University Medical Center | [18F]MH.MZ Bacterial penicillin-binding protein inhibitor | HTR2A, UNKNOWN, BDKRB2, Ion channels | Phase 4 | Neurodegenerative Diseases; Osteoarthritis, Knee; Pain; Intradialytic Hypotension … | Nov 2026 |
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| Vanda Pharmaceuticals | iloperidone Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR2A | Phase 4 | Schizophrenia; Hypertension | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| The University of Texas Health Science Center, Houston | ALA 10% gel Muscle-type nicotinic acetylcholine receptor antagonist | HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1 | Phase 4 | Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder … | Dec 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| John D. Dingell VA Medical Center | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Sleep Apnea | Dec 2026 |
| Tongji University | trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Depressed Insomniac Co-morbid Patients | Dec 2026 |
| The University of Texas Health Science Center at San Antonio | Pimavanserin Serotonin 2a (5-HT2a) receptor inverse agonist | HTR2A | Phase 4 | Parkinson's Disease Psychosis | Feb 2027 |
| The University of Texas Health Science Center at San Antonio | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Parkinson's Disease Psychosis | Feb 2027 |
| University of Texas Southwestern Medical Center | clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Apr 2027 |
| VA Office of Research and Development | pimavanserin Serotonin 2a (5-HT2a) receptor inverse agonist | HTR2A | Phase 4 | Parkinson's Disease Psychosis; Post-traumatic Stress Disorder | Jul 2027 |
| The Chaim Sheba Medical Center | risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Velocardiofacial Syndrome | Aug 2027 |
| Centre Hospitalier Universitaire, Amiens | clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Clozapine | Sep 2027 |
| Centre for Addiction and Mental Health | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Sep 2027 |
| Centre for Addiction and Mental Health | Paliperidone Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR2A | Phase 4 | Schizophrenia and Related Disorders | Sep 2027 |
| Centre for Addiction and Mental Health | Risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Schizophrenia and Related Disorders | Sep 2027 |
| New York State Psychiatric Institute | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Jun 2028 |
| Dr. Inge Winter | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia and Related Disorders | Jun 2028 |
| Northwell Health | aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 4 | Psychosis; Acute; Schizophenia Disorder | Dec 2029 |
| Northwell Health | risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Psychosis; Acute; Schizophenia Disorder | Dec 2029 |
| Jimmi Nielsen | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Dec 2029 |
| Massachusetts General Hospital | Aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 4 | Bipolar I Disorder | Feb 2030 |
| Massachusetts General Hospital | Lurasidone Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Bipolar I Disorder | Feb 2030 |
| Massachusetts General Hospital | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Bipolar I Disorder | Feb 2030 |
| VA Office of Research and Development | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Sleep Disordered Breathing | Jun 2030 |
| Northwell Health | clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophenia Disorder | Jul 2030 |
| Madigan Army Medical Center | Cyclobenzaprine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 4 | Low Back Pain | – |
| Chinese University of Hong Kong | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Mild Cognitive Impairment | – |
| COMPASS Pathways | Psilocybin (COMP360) Serotonin 2a (5-HT2a) receptor agonist | HTR2A | Phase 3 | Treatment Resistant Depression; Major Depressive Disorder; PTSD - Post Traumatic Stress Disorder; Depressive Disorder, Major … | Dec 2026 |
| Definium Therapeutics US | DT120 5-HT2A receptor agonist | HTR2A | Phase 3 | Major Depressive Disorder; Generalized Anxiety Disorder | Feb 2027 |
| Intra-Cellular Therapies | Lumateperone Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor | HTR2A, DRD2, SLC6A4 | Phase 3 | Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia … | Apr 2027 |
| Cybin IRL | CYB003 Deuterated psilocin analog | HTR2A | Phase 3 | Major Depressive Disorder; Major Depressive Disorder (MDD); Depression | Jun 2027 |
| Shanghai Mental Health Center | Aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 3 | Treatment-resistant Schizophrenia; Obsessive-Compulsive Disorder | Jun 2027 |
| Otsuka | Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 3 | Acute Schizophrenia | Sep 2027 |
| ACADIA Pharmaceuticals | ACP-204 5-HT2A receptor antagonist/inverse agonist | HTR2A | Phase 3 | Lewy Body Dementia Psychosis; Alzheimer's Disease Psychosis | Jan 2028 |
| Foundation for Advancing Veterans' Health Research | Quetiapine Fumarate Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 3 | Mild Traumatic Brain Injury | Jun 2028 |
| Shanghai Mental Health Center | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 3 | Treatment-resistant Schizophrenia | Dec 2030 |
| University of North Carolina, Chapel Hill | Cyclobenzaprine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 2 | Acute Stress Reaction | Nov 2026 |
| Washington State University | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Stimulant Use Disorder | Dec 2026 |
| University of Michigan | Cyclobenzaprine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 2 | High Tone Pelvic Floor Dysfunction | Dec 2026 |
| University of Trieste | mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | RETT Syndrome With Proven MECP2 Mutation | Dec 2026 |
| Ohio State University | Pimavanserin Serotonin 2a (5-HT2a) receptor inverse agonist | HTR2A | Phase 2 | Intermittent Explosive Disorder | Jan 2027 |
| M.D. Anderson Cancer Center | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium | Feb 2027 |
| M.D. Anderson Cancer Center | Haloperidol Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium; Advanced Malignant Neoplasm; Advanced Cancers | Feb 2027 |
| Boryung Pharmaceutical | Olanzapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy … | May 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 2 | Insomnia Chronic | Jul 2027 |
| Hospices Civils de Lyon | [18F]-altanserin 5-HT2A receptor ligand for PET imaging | HTR2A | Phase 2 | Tourette Disorder | Sep 2027 |
| Memorial Sloan Kettering Cancer Center | Flibanserin Serotonin 1A receptor agonist, serotonin 2A receptor antagonist, and serotonin reuptake in | HTR1A, HTR2A, SLC6A4 | Phase 2 | Breast Cancer | Oct 2027 |
| New York State Psychiatric Institute | Pimavanserin Tartrate Serotonin 2a (5-HT2a) receptor inverse agonist | HTR2A | Phase 2 | Autism Spectrum Disorder | Oct 2027 |
| M.D. Anderson Cancer Center | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Advanced Cancer | Dec 2027 |
| NeuroRx | NRX-101 D-cycloserine (NMDA co-agonist/glycine site modulator) + Lurasidone (5-HT and dopamine ant | GLRA1, HTR2A | Phase 2 | Treatment Resistant Depression | Dec 2027 |
| Tonix Pharmaceuticals | Cyclobenzaprine Hydrochloride (TNX-102) Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | HTR2A, HTR2C | Phase 2 | Major Depressive Episode (MDE); Pharmakokinetic | Feb 2028 |
| Lone Baandrup | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 2 | Psychiatric Disorders | Feb 2029 |
| Icahn School of Medicine at Mount Sinai | Pimavanserin Serotonin 2a (5-HT2a) receptor inverse agonist | HTR2A | Phase 2 | Major Depressive Disorder | Mar 2029 |
| Centre Hospitalier St Anne | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 2 | Depression - Major Depressive Disorder | Dec 2029 |
| University of California, Irvine | Mirtazapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Adrenergic receptor alpha-2 antagonist | HTR2A, HTR2C, ADRA2A, ADRA2C, ADRA2B | Phase 2 | Glioma of Brain | Dec 2030 |
| TRYP Therapeutics | TRP-8802 Psilocybin; serotonin 5-HT2A receptor agonist | HTR2A | Phase 2 | Irritable Bowel Syndrome | – |
| Md. Moktadirul Hoque Shuvo | Trifluoperazine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Functional Dyspepsia | – |
| Yale University | Dimethyltryptamine (DMT) Serotonin 5-HT receptor agonist; endogenous psychedelic compound | HTR1A, HTR1B, HTR1D, HTR2A | Phase 1 | Major Depressive Disorder; Alcohol Use Disorder (AUD) | Dec 2026 |
| University of Arizona | Ziprasidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 1 | Schizophrenia | Feb 2027 |
| Sichuan Kelun Pharmaceutical | Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 1 | Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder | – |
| Capital Medical University | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 1 | Acute Ischemic Stroke | – |
| University Hospital, Basel, Switzerland | Ketanserin Serotonin 5-HT2A receptor antagonist | HTR2A | Phase 1 | Healthy | – |
| Scottsdale Research Institute | Organic Whole Psilocybin-Containing Mushrooms Psilocybin (5-HT2A serotonin receptor agonist) | HTR2A | Phase 1 | PTSD | – |
| Verinder Sharma | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 1 | Postpartum Depression | – |
Major Depressive Disorder (15) Schizophrenia (11) Alcohol Use Disorder (10) Treatment Resistant Depression (8) Opioid Use Disorder (7) Healthy (6) Multiple Sclerosis (6) PTSD (5) Alcohol Use Disorder (AUD) (5) Depression (4) Advanced Cancer (4) Post Traumatic Stress Disorder (4)
small molecule (64), protein or peptide (3)
M.D. Anderson Cancer Center (3) Centre for Addiction and Mental Health (3) Northwell Health (3) Massachusetts General Hospital (3) VA Office of Research and Development (2) Shanghai Mental Health Center (2) New York State Psychiatric Institute (2) The University of Texas Health Science Center at San Antonio (2) Cybin IRL (1) Scottsdale Research Institute (1) COMPASS Pathways (1) ACADIA Pharmaceuticals (1) Vanda Pharmaceuticals (1) Intra-Cellular Therapies (1) Definium Therapeutics US (1) The Chaim Sheba Medical Center (1) Memorial Sloan Kettering Cancer Center (1) Verinder Sharma (1) Sichuan Kelun Pharmaceutical (1) Johns Hopkins University (1)
DRD2 (31) HTR2C (27) SLC6A4 (10) HTR1A (7) ADRA2A (5) ADRA2C (5) ADRA2B (5) DRD3 (5) DRD4 (5) OPRM1 (3) CNR1 (2) ADRB2 (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.